Ying Zhang

Ying Zhang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
HMHector Alvarez Manzo
Hector Alvarez Manzo
YZYumin Zhang
Yumin Zhang
WSWanliang Shi
Wanliang Shi
YZYing Zhang
Ying Zhang
Lyme disease, caused by Borrelia burgdorferi, is the most common vector-borne disease in USA, and 10–20% of patients will develop persistent symptoms despite treatment (“post-treatment Lyme disease syndrome”). B. burgdorferi persisters, which are not killed by the current antibiotics for Lyme disease, are considered one possible cause. Disulfiram has shown to be active against B. burgdorferi, but its activity against persistent forms is not well characterized. We assessed disulfiram as single drug and in combinations against stationary-phase B. burgdorferi culture enriched with persisters. Disulfiram was not very effective in the drug exposure experiment (survival rate (SR) 46.3%) or in combinations. Clarithromycin (SR 41.1%) and nitroxoline (SR 37.5%) were equally effective when compared to the current Lyme antibiotic cefuroxime (SR 36.8%) and more active than disulfiram. Cefuroxime + clarithromycin (SR 25.9%) and cefuroxime + nitroxoline (SR 27.5%) were significantly more active than cefuroxime + disulfiram (SR 41.7%). When replacing disulfiram with clarithromycin or nitroxoline in three-drug combinations, bacterial viability decreased significantly and subculture studies showed that combinations with these two drugs (cefuroxime + clarithromycin/nitroxoline + furazolidone/nitazoxanide) inhibited the regrowth, while disulfiram combinations did not (cefuroxime + disulfiram + furazolidone/nitazoxanide). Thus, clarithromycin and nitroxoline should be further assessed to determine their role as potential treatment alternatives in the future.

23 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
XMXiao Ma
Xiao Ma
JLJacob Leone
Jacob Leone
SSSunjya Schweig
Sunjya Schweig
YZYing Zhang
Ying Zhang
Bartonella henselae is a Gram-negative, facultative intracellular bacterium which is the causative agent of cat scratch disease. In humans, infections with B. henselae can result in acute or chronic systemic infections with various clinical symptoms including local skin lesions, malaise, aches, chills, lymphadenopathy, endocarditis, or meningoencephalitis. The current treatment for Bartonella infections with antibiotics such as doxycycline and rifampin is not always effective presumably due to bacterial persistence. There have been various anecdotal reports of herbal extracts used for treating patients with persistent Bartonella infections but their activity on B. henselae is unknown. To test the potential antimicrobial activity of botanical or herbal medicines and develop better therapies for persistent Bartonella infections, in this study, we screened an herbal product collection against stationary phase B. henselae in vitro using SYBR Green I/ propidium iodide (PI) viability assay. These herbal medicines were selected by the fact that they are commonly used to treat Lyme and co-infections by patients and herbalists, and as a follow-up to our recent study where these herbs were tested against B. burgdorferi . We identified five herbal product extracts that had high activity against stationary phase B. henselae at 0.5% ( v/v ), including Cryptolepis sanguinolenta , Juglans nigra , Polygonum cuspidatum , Scutellaria baicalensis , and Scutellaria barbata . Among them, Cryptolepis sanguinolenta , Juglans nigra , and Polygonum cuspidatum could eradicate all stationary phase B. henselae cells within 7 days at 0.25% ( v/v ) in drug exposure time-kill assay, whereas Scutellaria baicalensis and Scutellaria barbata showed relatively poor activity. The minimum inhibitory concentration (MIC) determination of these top hits indicated they were not only active against stationary phase non-growing B. henselae but also had good activity against log phase growing B. henselae . Our findings may help to develop more effective treatments for persistent Bartonella infections.

12 January 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
YZYumin Zhang
Yumin Zhang
HMHector Alvarez Manzo
Hector Alvarez Manzo
YZYing Zhang
Ying Zhang
We studied the effect of oxygen concentrations on the in vitro growth and drug susceptibility of Babesia duncani . We found that the growth of B. duncani required high level oxygen and the culture condition at ambient aerobic condition (21% O 2 ) was optimal. Compared with ambient air, our results further showed that low oxygen (6-16%) could arrest B. duncani schizonts and lead to high susceptibilities to antiparasitic drugs atovaquone, pyrimethamine, quinine, and chloroquine at certain concentrations in vitro. Drug susceptibilities of other Babesia spp impacted by O 2 levels need to be studied in the future, and this study indicates that culturing conditions of Babesia spp should be considered and reestablished for generating more comparable and reliable results in drug research in the future. Graphical Highlights: The in vitro growth of B. duncani requires high level oxygen and the culture condition of 5% CO 2 ambient air is optimal Low level oxygen results B. duncani in low growth rate and high schizont ratio in vitro Compared with 5% CO 2 ambient air, in vitro drug susceptibilities of B. duncani can be significantly increased when cultured in microaerobic condition